Hikma debuts docetaxel injection
Docetaxel injection had a market value of roughly $10 million in the 12 months ended March 2021, according to IQVIA.
Hikma is offering docetaxel injection in 20mg/mL and 80mg/4mL doses.
Docetaxel is an antineoplastic agent belonging to the taxoid family. It is indicated for the treatment of patients with locally advanced or metastatic cancer, including breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma and head and neck cancer.
Docetaxel injection had a market value of approximately $10 million in the 12 months ended March 2021, according to IQVIA.